文献速递肾小球疾病

吗替麦考酚酯与环磷酰胺用于儿童起病增殖性狼疮肾炎初始治疗:前瞻性多中心随机试验

Mycophenolate Mofetil versus Cyclophosphamide for Initial Therapy in Childhood-Onset Proliferative Lupus Nephritis: A Prospective, Multicenter, Randomized Trial.
PubMed 文献 · J Am Soc Nephrol · 2025-09-12

该前瞻性多中心随机试验纳入107例5–17岁增殖性狼疮肾炎患儿,比较口服吗替麦考酚酯(MMF)与静脉环磷酰胺初始治疗的24周总肾脏缓解率。MMF组总肾脏缓解率92% vs 环磷酰胺组89%,非劣效检验P=0.008,两组药物不良反应发生率无显著差异。

要点

  • MMF组总肾脏缓解率非劣效于环磷酰胺组(92% vs 89%,非劣效P=0.008)。
  • 两组药物不良反应发生率无显著差异(10% vs 15%,P=0.44)。
  • 两组SLE疾病活动指数评分下降相似。

核心结论

  • 治疗24周后,口服MMF作为儿童起病增殖性狼疮肾炎初始治疗非劣效于静脉环磷酰胺,且安全性特征相似。

研究设计与样本

  • 前瞻性、多中心、随机试验,纳入5–17岁增殖性狼疮肾炎(3/4±5型)且严重蛋白尿(尿蛋白-肌酐比≥1000 mg/g和/或24小时尿蛋白排泄>25 mg/kg)患者,随机接受MMF或静脉环磷酰胺初始治疗,同时使用糖皮质激素。
  • 共纳入107例患者,来自17家医院,MMF组52例(47例完成24周治疗),环磷酰胺组55例(48例完成24周治疗)。
  • 主要终点为24周总肾脏缓解(TRR),非劣效界值12%。

主要发现

  • 意向治疗人群中,MMF组TRR率92% vs 环磷酰胺组89%(非劣效检验P=0.008)。
  • 符合方案人群中,MMF组肾脏缓解率96% vs 环磷酰胺组94%(非劣效检验P=0.009)。
  • 意向治疗人群中TRR率差值MMF组 vs 环磷酰胺组为3%(95%CI −9%至15%);符合方案人群为2%(95%CI −9%至13%)。
  • 意向治疗人群中药物不良反应发生率MMF组10% vs 环磷酰胺组15%(连续性校正卡方检验P=0.44),无显著差异。

关键数值与推荐

  • 总肾脏缓解包括完全肾脏缓解、主要疗效肾脏缓解和部分肾脏缓解。
  • 非劣效界值为12%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: The total renal response rate in the mycophenolate mofetil group was found to be noninferior to that in the cyclophosphamide group. There was no significant difference in the incidence of adverse drug reactions between the mycophenolate mofetil and cyclophosphamide groups. The reduction in SLE Disease Activity Index scores was similar between the two groups. BACKGROUND: Recent studies suggest that oral mycophenolate mofetil (MMF) may be similar to intravenous cyclophosphamide in treating lupus nephritis. However, these therapies have not been prospectively compared in childhood-onset lupus nephritis. METHODS: In this prospective, multicenter, randomized trial, patients aged 5–17 years with proliferative lupus nephritis (class 3/4±5) and severely increased proteinuria (urine protein-creatinine ratio ≥1000 mg/g and/or 24-hour urinary protein excretion >25 mg/kg) were randomly assigned to receive either MMF or intravenous cyclophosphamide as initial therapy, alongside glucocorticoids. The primary end point was total renal response (TRR) at 24 weeks, with the aim of demonstrating the noninferiority of MMF compared with intravenous cyclophosphamide, using a noninferiority margin of 12%. TRR encompassed complete renal response, primary efficacy renal response, and partial renal response. Secondary end points assessed systemic disease activity and safety. RESULTS: A total of 107 patients were enrolled from 17 hospitals, with 52 assigned to the MMF group (47 completed the 24-week therapy) and 55 assigned to the cyclophosphamide group (48 completed the 24-week therapy). In the intention-to-treat population, the TRR rate was 92% in the MMF group and 89% in the cyclophosphamide group (test for noninferiority, P = 0.008). In the per-protocol population, renal response was observed in 96% of patients in the MMF group versus 94% of patients in the cyclophosphamide group (test for noninferiority, P = 0.009). The difference in TRR rate between the MMF and cyclophosphamide groups was 3% (95% confidence interval, −9% to 15%) in the intention-to-treat population and 2% (95% confidence interval, −9% to 13%) in the per-protocol population. There were no significant differences in the incidence of adverse drug reactions between the MMF and cyclophosphamide groups in the intention-to-treat population (10% versus 15%, continuity correction chi-squared test, P = 0.44). CONCLUSIONS: After 24 weeks of therapy, oral MMF was noninferior to intravenous cyclophosphamide as initial therapy for childhood-onset proliferative lupus nephritis and exhibited a similar safety profile. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: MMF versus cyclophosphamide in the Induction Therapy of Pediatric Active Proliferative lupus nephritis, ClinicalTrials.gov, NCT05495893.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Li X, Jian S, et al. Mycophenolate Mofetil versus Cyclophosphamide for Initial Therapy in Childhood-Onset Proliferative Lupus Nephritis: A Prospective, Multicenter, Randomized Trial. J Am Soc Nephrol. 2025. PMID: 40938672. doi:10.1681/ASN.0000000866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。